Trial · NCT01292005
Pentoxifylline Treatment of Acute Pancreatitis
NCT01292005, Early phase 1, Completed, Mayo Clinic; results first posted 2013-12-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pentoxifylline Treatment of Acute Pancreatitis. Trials, record NCT01292005. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01292005
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pentoxifylline Treatment of Acute Pancreatitis
- NCT number
- NCT01292005
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 28 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Acute Pancreatitis
- Interventions
- Pentoxifylline, Placebo
- First posted
- 2011-02-09
- Last updated
- 2016-10-25
- Results first posted
- 2013-12-13
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in C-Reactive Protein (CRP) | baseline, Day 1, Day 3 | C-reactive protein is produced by the liver. The level of CRP rises when there is inflammation throughout the body. The normal value range for CRP = 1-10 mg/L. |
| Primary | Change in Tumor Necrosis Factor (TNF)-Alpha | baseline, Day 1, Day 3 | Normal value range for TNF alpha = 0 - 22 pg/ml. |
| Primary | Change in Interleukin (IL) IL-6 | baseline, Day 1, Day 3 | Normal value range for IL-6 = 0 - 5 pg/ml. |
| Primary | Changes in Interleukin (IL) IL-8 | baseline, Day 1, Day 3 | Normal value range for IL-8 = 0 - 5 pg/ml. |
| Secondary | Number Of Subjects With New Onset Organ Failure During Hospitalization | 1 week or until dismissal date whichever occurs earlier. | |
| Secondary | Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization | 1 week or until dismissal date whichever occurs earlier | |
| Secondary | Number of Patients With Lengthy Hospital Stays | 30 days or until dismissal date, whichever occurs earlier | "Lengthy" was defined as either greater than 4 days or greater than 10 days. |
| Secondary | Length of Hospital Stay | 30 days or until dismissal date, whichever occurs earlier | |
| Secondary | Length of Intensive Care Unit (ICU) Stay | 30 days or until dismissal date, whichever occurs earlier | |
| Secondary | Number of Subjects Who Needed an Intensive Care Unit Stay | 30 days, or until dismissal, whichever came first |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in C-Reactive Protein (CRP) | baseline, Day 1, Day 3 | mg/L | MEDIAN | |
| PRIMARY | Change in Tumor Necrosis Factor (TNF)-Alpha | baseline, Day 1, Day 3 | pg/ml | MEDIAN | |
| PRIMARY | Change in Interleukin (IL) IL-6 | baseline, Day 1, Day 3 | pg/ml | MEDIAN | |
| PRIMARY | Changes in Interleukin (IL) IL-8 | baseline, Day 1, Day 3 | pg/ml | MEDIAN | |
| SECONDARY | Number Of Subjects With New Onset Organ Failure During Hospitalization | 1 week or until dismissal date whichever occurs earlier. | participants | NUMBER | |
| SECONDARY | Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization | 1 week or until dismissal date whichever occurs earlier | participants | NUMBER | |
| SECONDARY | Number of Patients With Lengthy Hospital Stays | 30 days or until dismissal date, whichever occurs earlier | participants | NUMBER | |
| SECONDARY | Length of Hospital Stay | 30 days or until dismissal date, whichever occurs earlier | days | MEDIAN | |
| SECONDARY | Length of Intensive Care Unit (ICU) Stay | 30 days or until dismissal date, whichever occurs earlier | Days | MEDIAN | |
| SECONDARY | Number of Subjects Who Needed an Intensive Care Unit Stay | 30 days, or until dismissal, whichever came first | participants | NUMBER |
Source ClinicalTrials.gov
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in C-Reactive Protein (CRP) | Pentoxifylline | Change from baseline to Day 1 | 48.4 | Full Range -37.1 to 207.3 | mg/L |
| Change in C-Reactive Protein (CRP) | Placebo | Change from baseline to Day 1 | 60.6 | Full Range -71 to 283.2 | mg/L |
| Change in C-Reactive Protein (CRP) | Pentoxifylline | Change from baseline to Day 3 | 62 | Full Range -157.4 to 255.3 | mg/L |
| Change in C-Reactive Protein (CRP) | Placebo | Change from baseline to Day 3 | 154 | Full Range -170 to 193.5 | mg/L |
| Change in Tumor Necrosis Factor (TNF)-Alpha | Pentoxifylline | Change from baseline to Day 1 | 0 | Full Range -1.2 to 0.52 | pg/ml |
| Change in Tumor Necrosis Factor (TNF)-Alpha | Placebo | Change from baseline to Day 1 | -0.05 | Full Range -0.9 to 49.2 | pg/ml |
| Change in Tumor Necrosis Factor (TNF)-Alpha | Pentoxifylline | Change from baseline to Day 3 | 0.2 | Full Range -1.0 to 0.5 | pg/ml |
| Change in Tumor Necrosis Factor (TNF)-Alpha | Placebo | Change from baseline to Day 3 | -0.3 | Full Range -3.5 to 17.2 | pg/ml |
| Change in Interleukin (IL) IL-6 | Pentoxifylline | Change from baseline to Day 1 | 2.1 | Full Range -37 to 25 | pg/ml |
| Change in Interleukin (IL) IL-6 | Placebo | Change from baseline to Day 1 | 0.7 | Full Range -62 to 152 | pg/ml |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pentoxifylline | 14 | |
| Overall Study | STARTED | Placebo | 14 | |
| Overall Study | COMPLETED | Pentoxifylline | 14 | |
| Overall Study | COMPLETED | Placebo | 14 | |
| Overall Study | NOT COMPLETED | Pentoxifylline | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pentoxifylline | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Pentoxifylline | 0 | 14 |
| Total, other adverse events | Placebo | 0 | 14 |
| Total, serious adverse events | Pentoxifylline | 0 | 14 |
| Total, serious adverse events | Placebo | 0 | 14 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26112745 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Pentoxifylline vs Placebo: Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization | Trial comparisons |
| Pentoxifylline vs Placebo: Number Of Subjects With New Onset Organ Failure During Hospitalization | Trial comparisons |
| Pentoxifylline vs Placebo: Number of Subjects Who Needed an Intensive Care Unit Stay | Trial comparisons |
| Pentoxifylline vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01292005
GET https://conductscience.org/api/trials/v1/NCT01292005/results?page=2